Keros Therapeutics, Inc. (KROS) stock
KROSNasdaqPharmaceutical PreparationsFiscal year ends December 31
$11.31+1.28 (+12.76%)
Close on Nov 17, 2026Market cap $224.25MP/E –Yield –
Keros Therapeutics cash
Cash and short-term investments held at the end of each period.
Keros Therapeutics's cash was $257.61M at Jun 30, 2026. For fiscal 2025 it was $287.42M, down 48.8% from the year before. The highest annual figure on record is $561.38M in fiscal 2024.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $287.42M | -48.8% |
| FY2024 | Dec 31, 2024 | $561.38M | +68.9% |
| FY2023 | Dec 31, 2023 | $332.36M | +19.1% |
| FY2022 | Dec 31, 2022 | $279.05M | +20.6% |
| FY2021 | Dec 31, 2021 | $231.37M | -13.0% |
| FY2020 | Dec 31, 2020 | $265.99M | +3628.0% |
| FY2019 | Dec 31, 2019 | $7.14M | -69.5% |
| FY2018 | Dec 31, 2018 | $23.39M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $257.61M | -62.7% |
| Q1 FY2026 | Mar 31, 2026 | $281.50M | -60.9% |
| Q4 FY2025 | Dec 31, 2025 | $287.42M | -48.8% |
| Q3 FY2025 | Sep 30, 2025 | $693.47M | +30.7% |
| Q2 FY2025 | Jun 30, 2025 | $690.22M | +70.1% |
| Q1 FY2025 | Mar 31, 2025 | $720.54M | +62.9% |
| Q4 FY2024 | Dec 31, 2024 | $561.38M | +68.9% |
| Q3 FY2024 | Sep 30, 2024 | $530.68M | +84.3% |
| Q2 FY2024 | Jun 30, 2024 | $405.86M | +26.0% |
| Q1 FY2024 | Mar 31, 2024 | $442.44M | +25.9% |
| Q4 FY2023 | Dec 31, 2023 | $332.36M | +19.1% |
| Q3 FY2023 | Sep 30, 2023 | $287.89M | +20.2% |
| Q2 FY2023 | Jun 30, 2023 | $322.03M | +49.3% |
| Q1 FY2023 | Mar 31, 2023 | $351.43M | +53.7% |
| Q4 FY2022 | Dec 31, 2022 | $279.05M | +20.6% |
| Q3 FY2022 | Sep 30, 2022 | $239.43M | +8.2% |
| Q2 FY2022 | Jun 30, 2022 | $215.62M | -9.1% |
| Q1 FY2022 | Mar 31, 2022 | $228.59M | -10.4% |
| Q4 FY2021 | Dec 31, 2021 | $231.37M | -13.0% |
| Q3 FY2021 | Sep 30, 2021 | $221.35M | +65.4% |
| Q2 FY2021 | Jun 30, 2021 | $237.11M | +63.9% |
| Q1 FY2021 | Mar 31, 2021 | $255.20M | +368.1% |
| Q4 FY2020 | Dec 31, 2020 | $265.99M | +3628.0% |
| Q3 FY2020 | Sep 30, 2020 | $133.81M | +967.7% |
| Q2 FY2020 | Jun 30, 2020 | $144.69M | +830.6% |
| Q1 FY2020 | Mar 31, 2020 | $54.52M | +162.8% |
| Q4 FY2019 | Dec 31, 2019 | $7.14M | -69.5% |
| Q3 FY2019 | Sep 30, 2019 | $12.53M | – |
| Q2 FY2019 | Jun 30, 2019 | $15.55M | – |
| Q1 FY2019 | Mar 31, 2019 | $20.75M | – |
| Q4 FY2018 | Dec 31, 2018 | $23.39M | – |
See a number that looks wrong?